){kind=logo}
){kind=logo}
NICE backs new therapy for advanced prostate cancer amid concerns over availability
When combined with hormone therapy (ADT), it offers similar benefits to existing treatments but with fewer side effects, making it especially suitable for older men or those who cannot tolerate chemotherapy or other advanced therapies.
However, access to the best treatments remains highly unequal. Data from the National Prostate Cancer Audit shows that less than half (47%) of eligible men receive the latest NICE-recommended therapies. In some regions, fewer than 40% get optimal care. Men who are Black, older, or living in deprived areas are disproportionately affected by this “postcode lottery.”
Prostate Cancer UK is urging the Government to address these inequities. They stress that NICE approval is only the first step; the new National Cancer Plan must ensure consistent delivery of effective treatments like darolutamide.
The charity is also calling for urgent action on early detection, noting that only half of prostate cancers are diagnosed at an early, more treatable stage. They advocate for updated GP guidance so doctors can proactively reach out to men at highest risk. Supporters are encouraged to join their campaign and sign up for updates.